APP
PROF

Alpha Paradigm Partners’s Profound Medical PROF Stock Holding History

Alpha Paradigm Partners’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,262
Closed -$18K – 641
2021
Q3 		$18K Buy
+1,262
New +$19.2K 0.01% 499

Other funds holding PROF

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BC
Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Alpha Paradigm Partners's PROF Position: Q4 2021 in Review

Alpha Paradigm Partners sold out of Profound Medical (PROF) in Q4 2021, closing a stake of 1,262 shares — an estimated $18K sold.

Alpha Paradigm Partners first reported a position in PROF in Q3 2021 and held it in 1 quarter. The position peaked at $18K in Q3 2021. 46 funds tracked by Wall St. Rank hold PROF as of Q4 2021.

  • Alpha Paradigm Partners reported no remaining Profound Medical position as of Q4 2021 after selling out during the quarter.
  • Alpha Paradigm Partners sold 1,262 Profound Medical shares in Q4 2021, an estimated $18K.
  • Alpha Paradigm Partners first reported a position in Profound Medical in Q3 2021 and held it in 1 quarter.
  • Alpha Paradigm Partners's Profound Medical position peaked at $18K in Q3 2021.
  • 46 funds tracked by Wall St. Rank held Profound Medical as of Q4 2021.

Based on Alpha Paradigm Partners's 13F filing for Q4 2021, filed 14 Feb 2022.